>
Switch to:

Akero Therapeutics EV-to-EBIT

: -11.84 (As of Today)
View and export this data going back to 2019. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Akero Therapeutics's Enterprise Value is $788.46 Mil. Akero Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 was $-66.59 Mil. Therefore, Akero Therapeutics's EV-to-EBIT for today is -11.84.

NAS:AKRO' s EV-to-EBIT Range Over the Past 10 Years
Min: -79.64   Med: 0   Max: 0
Current: -11.84

-79.64
0
NAS:AKRO's EV-to-EBIT is ranked lower than
99.99% of the 245 Companies
in the Biotechnology industry.

( Industry Median: 36.01 vs. NAS:AKRO: -11.84 )

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Akero Therapeutics's Enterprise Value for the quarter that ended in Sep. 2020 was $756.95 Mil. Akero Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 was $-66.59 Mil. Akero Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2020 was -8.80%.


Akero Therapeutics EV-to-EBIT Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Akero Therapeutics Annual Data
Dec17 Dec18 Dec19
EV-to-EBIT 0.00 0.00 -10.90

Akero Therapeutics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.49 -10.90 -9.12 0.00 0.00

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Akero Therapeutics EV-to-EBIT Distribution

* The bar in red indicates where Akero Therapeutics's EV-to-EBIT falls into.



Akero Therapeutics EV-to-EBIT Calculation

Akero Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=788.458/-66.592
=-11.84

Akero Therapeutics's current Enterprise Value is $788.46 Mil.
Akero Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 was -16.221 (Dec. 2019 ) + -12.379 (Mar. 2020 ) + -16.454 (Jun. 2020 ) + -21.538 (Sep. 2020 ) = $-66.59 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Akero Therapeutics  (NAS:AKRO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Akero Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2020 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2020 ) =EBIT / Enterprise Value (Q: Sep. 2020 )
=-66.592/756.94937
=-8.80 %

Akero Therapeutics's Enterprise Value for the quarter that ended in Sep. 2020 was $756.95 Mil.
Akero Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 was -16.221 (Dec. 2019 ) + -12.379 (Mar. 2020 ) + -16.454 (Jun. 2020 ) + -21.538 (Sep. 2020 ) = $-66.59 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Akero Therapeutics EV-to-EBIT Related Terms


Akero Therapeutics EV-to-EBIT Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)